In 2006, a few hundred mostly local researchers gathered in La Jolla to discuss the emerging but still science-fictiony field of stem cells. Since then, stem cells, enhanced by gene therapy, have progressed to yield breakthrough treatments, most spectacularly in cancer. Likewise, the conference known as the Cell & Gene Meeting on the Mesa has mushroomed into an international event.
What started out as a “scientific symposium” on stem cells has grown into a three-day conference with talks, corporate presentations, and a partnering forum for cell and gene therapies. The Cell and Gene Meeting on the Mesa will bring together over 1,000 attendees who will take part in more than 1,450 one-on-one meetings to support partnering.
Cell- and gene-based therapies form one of the pillars of regenerative medicine. They have the potential to transform quality of life and improve the health status of patients with genetic and cellular defects, including genetic diseases, neurodegenerative diseases and tissue malignancies, amongst others. Despite numerous challenges, in the last decade, tremendous unified efforts by research and clinical scientists in academic, translational and industry settings have resulted in tangible outcomes in the form of many marketing authorizations and approved commercial firsts
Cell and gene therapies hold the potential to transform medicine; however, if patients are to gain access to these therapies, we must increase public awareness and understanding of how these therapies can benefit them. According to a review of recent research studies that measured U.S. public opinion related to gene medicine,1 the public is not yet aware of gene medicine; is unfamiliar with the terms being used to describe the topic; and, when faced with multiple therapeutic options, is worried about making informed decisions.
